← Back to Search

GLP-1 Receptor Agonist

Cohort 3 for Type 2 Diabetes

Phase 1
Waitlist Available
Research Sponsored by Hanmi Pharmaceutical Company Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month
Awards & highlights

Study Summary

This is a phase 1 multiple ascending dose (MAD) study, conducted in subjects with Type 1 and Type 2 diabetes mellitus

Eligible Conditions
  • Type 2 Diabetes
  • Type 1 Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with adverse events
Secondary outcome measures
AUC of HM12470
Cmax of HM12470

Trial Design

4Treatment groups
Experimental Treatment
Group I: Cohort 4Experimental Treatment1 Intervention
T2DM: Multiple dose subcutaneous administration
Group II: Cohort 3Experimental Treatment1 Intervention
T2DM: Multiple dose subcutaneous administration
Group III: Cohort 2Experimental Treatment1 Intervention
T1DM: Multiple dose subcutaneous administration
Group IV: Cohort 1Experimental Treatment1 Intervention
T1DM: Multiple dose subcutaneous administration
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
HM12470
2015
Completed Phase 1
~160

Find a Location

Who is running the clinical trial?

Hanmi Pharmaceutical Company LimitedLead Sponsor
190 Previous Clinical Trials
61,045 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Multiple Ascending Dose Study of HM12470 in Type 1 and Type 2 Diabetes Mellitus
2015. "Multiple Ascending Dose Study of HM12470 in Type 1 and Type 2 Diabetes Mellitus". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03332849.
All > Type 2 Diabetes
~6 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top